Results 1 to 10 of about 73,615 (295)

Influence of pharmacokinetics‐related gene polymorphisms on plasma levels of clozapine and its metabolites in Japanese patients with schizophrenia [PDF]

open access: yesPCN Reports
Aim Clozapine is an atypical antipsychotic drug that is most effective against treatment‐resistant schizophrenia and causes serious adverse effects, including agranulocytosis. We examined the relationships between age, sex, genetic polymorphisms, and the
Shinya Kinoshita   +5 more
doaj   +2 more sources

Clozapine cessation

open access: yesEuropean Psychiatry, 2022
Introduction Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant or refractory schizophrenia. The gold standard for treatment is clozapine.
H. Ktari   +6 more
doaj   +2 more sources

Underuse of recommended treatments among people living with treatment-resistant psychosis

open access: yesFrontiers in Psychiatry, 2022
BackgroundInternational guidelines recommend that individuals with treatment-resistant psychosis must be treated with clozapine. ECT has also been reported to improve symptom profiles.
Julia M. Lappin   +7 more
doaj   +1 more source

Point-of-care haematological monitoring during treatment with clozapine

open access: yesJournal of Laboratory Medicine, 2022
Patients treated with clozapine are required to have regular venous blood samples taken to measure white blood cell (WBC) and neutrophil counts to reduce the risk of agranulocytosis.
Atkins Matthew   +7 more
doaj   +1 more source

Elevated clozapine levels in patients with COVID-19 infection

open access: yesEuropean Psychiatry, 2021
Introduction Clozapine is the most effective antipsychotic for treatment resistant schizophrenia. In patients treated with clozapine, COVID-19 infection may result in complications including an increased risk of pneumonia, clozapine toxicity, and ...
J. Marti Bonany   +8 more
doaj   +1 more source

Clozapine prescription rates in Southeast Europe: A cross-sectional study

open access: yesFrontiers in Psychiatry, 2023
IntroductionInternational reports indicate that clozapine is under prescribed. Yet, this has not been explored in Southeast European (SEE) countries. This cross-sectional study investigates clozapine prescription rates in a sample of 401 outpatients with
Manuela Russo   +10 more
doaj   +1 more source

Clozapine-associated neutropenia following augmentation with sodium valproate

open access: yesSAGE Open Medical Case Reports, 2021
Clozapine is gold standard for the management of treatment-resistant schizophrenia. It can offer life-changing symptom reduction where other antipsychotics have failed, and for these patients, treatment with clozapine should be maintained, if in any ...
Michelle Iris Jakobsen   +3 more
doaj   +1 more source

Clozapine is strongly associated with the risk of pneumonia and inflammation

open access: yesGeneral Psychiatry, 2020
Clinicians need to remember that (1) systemic inflammations can increase clozapine level; (2) clozapine, by itself, can cause inflammation, particularly during titration that is too rapid for that patient; (3) clozapine may increase the risk of infection;
Chuanyue Wang   +3 more
doaj   +1 more source

Use of olanzapine compared with clozapine for treatment-resistant schizophrenia in a real-world setting: nationwide register-based study

open access: yesBJPsych Open, 2021
Background Clozapine is generally considered as the treatment of choice for patients with treatment-resistant schizophrenia (TRS). However, its superiority has recently been questioned because olanzapine has been suggested as non-inferior to clozapine ...
Young Tak Jo   +4 more
doaj   +1 more source

Relationship between clozapine exposure and the onset of appendicitis in schizophrenia patients: a retrospective cohort study

open access: yesBMC Psychiatry, 2022
Objective Clozapine may cause serious side effects despite benefits in patients with schizophrenia. Thus, an accurate understanding of the side-effect profile of clozapine is extremely important in the management of its administration to patients with ...
Yuta Kawakita   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy